Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

News Conference News TCT 2024

Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI

November 04, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

News Conference News TCT 2024

TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation

Michael O'Riordan

October 30, 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

News Conference News TCT 2024

ALIGN-AR at 2 Years Shows Promise for TAVI With Trilogy in Aortic Regurgitation

Yael L. Maxwell

October 29, 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

News Conference News TCT 2024

TRILUMINATE: More Patient Data Reassure on TEER’s Benefits for Severe TR

Michael O'Riordan

October 29, 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

News Conference News TCT 2024

EARLY TAVR Breaks New Ground for Preemptive Treatment of Asymptomatic AS

October 28, 2024

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

News Conference News TCT 2023

SUMMIT: MV Replacement With Tendyne Shows Promise in Severe MR, MAC

Yael L. Maxwell

October 30, 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

News Conference News TCT 2023

‘Big Step Forward’ for Transcatheter Tricuspid Valve Replacement: TRISCEND II

Michael O'Riordan

October 26, 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

News Conference News TCT 2023

More TRILUMINATE Patients Flesh Out Tricuspid TEER’s Impact

Yael L. Maxwell

October 24, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

News Conference News TCT 2022

Ultrasound for Femoral Access? Neutral Results vs Common Sense: UNIVERSAL

Yael L. Maxwell

September 19, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

News Conference News TCT 2021

Transcatheter Mitral, Tricuspid Valve Replacement Inch Forward

Yael L. Maxwell

November 06, 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

News Conference News TCT 2021

More Complications With Plug Closure After TAVI: CHOICE-CLOSURE

Michael O'Riordan

November 05, 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

News Conference News TCT 2020

Sapien 3 Stroke Rate Perplexes in 1-Year SOLVE-TAVI Results

Michael O'Riordan

October 16, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.